Uterine Cancer pp 183-199 | Cite as

Early-Stage Endometrial Cancer: Radiation—Less May Be More

  • Onyinye Balogun
  • Stella Lymberis
  • Peter B. SchiffEmail author
Part of the Current Clinical Oncology book series (CCO)


Due to its documented efficacy in improving locoregional control and reducing rates of vaginal vault recurrence, radiation therapy has been used as an adjunct to surgical intervention for the last 5 decades. Several randomized studies have established the role of adjuvant radiotherapy in decreasing local recurrence among patients at intermediate to high risk of local failure. External beam radiotherapy achieves local control at the cost of some morbidity but does not influence overall survival. Intracavitary brachytherapy has emerged as an alternative to external beam radiotherapy due to its overall lower morbidity. Trials are ongoing to determine the potential added benefit of chemotherapy to radiation therapy as well as to explore lower brachytherapy doses in early stage disease. For management of high risk, more advanced stage disease and carcinosarcoma, please see Chaps. 10, 11, and 13, respectively.


Endometrial cancer Brachytherapy External beam radiotherapy 


  1. 1.
    Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6):djv048.CrossRefGoogle Scholar
  2. 2.
    Kimura T, et al. Abnormal uterine bleeding and prognosis of endometrial cancer. Int J Gynaecol Obstet. 2004;85(2):145–50.CrossRefGoogle Scholar
  3. 3.
    Seebacher V, et al. The presence of postmenopausal bleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center study. BMC Cancer. 2009;9:460.CrossRefGoogle Scholar
  4. 4.
    Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009;105(2):109.CrossRefGoogle Scholar
  5. 5.
    Creutzberg CL, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404–11.CrossRefGoogle Scholar
  6. 6.
    Keys HM, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744–51.CrossRefGoogle Scholar
  7. 7.
    Huh WK, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer. 2007;17(4):886–9.CrossRefGoogle Scholar
  8. 8.
    Jereczek-Fossa B, Badzio A, Jassem J. Recurrent endometrial cancer after surgery alone: results of salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48(2):405–13.CrossRefGoogle Scholar
  9. 9.
    Nag S, et al. Interstitial brachytherapy for salvage treatment of vaginal recurrences in previously unirradiated endometrial cancer patients. Int J Radiat Oncol Biol Phys. 2002;54(4):1153–9.CrossRefGoogle Scholar
  10. 10.
    Petignat P, et al. Salvage treatment with high-dose-rate brachytherapy for isolated vaginal endometrial cancer recurrence. Gynecol Oncol. 2006;101(3):445–9.CrossRefGoogle Scholar
  11. 11.
    Creasman WT, et al. Significance of true surgical pathologic staging: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1999;181(1):31–4.CrossRefGoogle Scholar
  12. 12.
    Ben-Shachar I, et al. Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol. 2005;105(3):487–93.CrossRefGoogle Scholar
  13. 13.
    Mariani A, et al. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000;182(6):1506–19.CrossRefGoogle Scholar
  14. 14.
    Lee CM, et al. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA. 2006;295(4):389–97.CrossRefGoogle Scholar
  15. 15.
    Straughn Jr JM, et al. The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base. Gynecol Oncol. 2005;99(3):530–5.CrossRefGoogle Scholar
  16. 16.
    Nout RA, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol. 2011;29(13):1692–700.CrossRefGoogle Scholar
  17. 17.
    Aalders J, et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56(4):419–27.PubMedGoogle Scholar
  18. 18.
    ASTEC/EN.5 Study Group, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009;373(9658):137–46.CrossRefGoogle Scholar
  19. 19.
    Hogberg T, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer. 2010;46(13):2422–31.CrossRefGoogle Scholar
  20. 20.
    McMeekin DS, Filiaci VL, Aghajanian C. A randomized Phase III trial of pelvic radiation therapy (WPRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): a Gyencologic Oncology Group trial. In Society of Gynecologic Oncology Annual Meeting. 2014. Tampa, FL.Google Scholar
  21. 21.
    Viswanathan AN, et al. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015;121(13):2156–63.Google Scholar
  22. 22.
    Eltabbakh GH, et al. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. Int J Radiat Oncol Biol Phys. 1997;38(2):373–80.CrossRefGoogle Scholar
  23. 23.
    Alektiar KM, et al. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2005;62(1):111–7.CrossRefGoogle Scholar
  24. 24.
    Pearcey RG, Petereit DG. Post-operative high dose rate brachytherapy in patients with low to intermediate risk endometrial cancer. Radiother Oncol. 2000;56(1):17–22.CrossRefGoogle Scholar
  25. 25.
    Nout RA, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816–23.CrossRefGoogle Scholar
  26. 26.
    Creutzberg CL, et al. The morbidity of treatment for patients with Stage I endometrial cancer: results from a randomized trial. Int J Radiat Oncol Biol Phys. 2001;51(5):1246–55.CrossRefGoogle Scholar
  27. 27.
    Shih KK, et al. Pelvic insufficiency fractures in patients with cervical and endometrial cancer treated with postoperative pelvic radiation. Gynecol Oncol. 2013;128(3):540–3.CrossRefGoogle Scholar
  28. 28.
    Wiltink LM, et al. No increased risk of second cancer after radiotherapy in patients treated for rectal or endometrial cancer in the randomized TME, PORTEC-1, and PORTEC-2 trials. J Clin Oncol. 2015;33(15):1640–6.CrossRefGoogle Scholar
  29. 29.
    Alektiar KM, et al. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer. Int J Radiat Oncol Biol Phys. 2002;53(3):707–13.CrossRefGoogle Scholar
  30. 30.
    Horowitz NS, et al. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol. 2002;99(2):235–40.PubMedGoogle Scholar
  31. 31.
    Petereit DG, et al. Outpatient vaginal cuff brachytherapy for endometrial cancer. Int J Gynecol Cancer. 1999;9(6):456–62.CrossRefGoogle Scholar
  32. 32.
    Sorbe BG, Smeds AC. Postoperative vaginal irradiation with high dose rate afterloading technique in endometrial carcinoma stage I. Int J Radiat Oncol Biol Phys. 1990;18(2):305–14.CrossRefGoogle Scholar
  33. 33.
    Nout RA, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol. 2009;27(21):3547–56.CrossRefGoogle Scholar
  34. 34.
    Orton CG. High-dose-rate brachytherapy may be radiobiologically superior to low-dose rate due to slow repair of late-responding normal tissue cells. Int J Radiat Oncol Biol Phys. 2001;49(1):183–9.CrossRefGoogle Scholar
  35. 35.
    Bekerus M, et al. Comparison of HDR and LDR results in endometrium cancer. Sonderb Strahlenther Onkol. 1988;82:222–7.PubMedGoogle Scholar
  36. 36.
    Fayed A, et al. Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2007;67(2):480–4.CrossRefGoogle Scholar
  37. 37.
    Rauthe G, Vahrson H, Giers G. Five-year results and complications in endometrium cancer: HDR afterloading vs. conventional radium therapy. Sonderb Strahlenther Onkol. 1988;82:240–5.PubMedGoogle Scholar
  38. 38.
    Nag S, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys. 2000;48(3):779–90.CrossRefGoogle Scholar
  39. 39.
    Small Jr W, Erickson B, Kwakwa F. American Brachytherapy Society survey regarding practice patterns of postoperative irradiation for endometrial cancer: current status of vaginal brachytherapy. Int J Radiat Oncol Biol Phys. 2005;63(5):1502–7.CrossRefGoogle Scholar
  40. 40.
    Harkenrider MM. Preliminary Results of the American Brachytherapy Society Survey of Practice Patterns for Vaginal Brachytherapy for Postoperative Endometrial Cancer in ASTRO. 2014. San Francisco, CA.Google Scholar
  41. 41.
    Demanes DJ, et al. The use and advantages of a multichannel vaginal cylinder in high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;44(1):211–9.CrossRefGoogle Scholar
  42. 42.
    Maruyama Y, Ezzell G, Porter AT. Afterloading high dose rate intracavitary vaginal cylinder. Int J Radiat Oncol Biol Phys. 1994;30(2):473–6.CrossRefGoogle Scholar
  43. 43.
    Park SJ, et al. Dosimetric comparison of 3-dimensional planning techniques using an intravaginal multichannel balloon applicator for high-dose-rate gynecologic brachytherapy. Int J Radiat Oncol Biol Phys. 2013;87(4):840–6.CrossRefGoogle Scholar
  44. 44.
    Tanderup K, Lindegaard JC. Multi-channel intracavitary vaginal brachytherapy using three-dimensional optimization of source geometry. Radiother Oncol. 2004;70(1):81–5.CrossRefGoogle Scholar
  45. 45.
    Gloi AM. First clinical implementation of the Capri applicator. J Appl Clin Med Phys. 2014;15(1):4581.CrossRefGoogle Scholar
  46. 46.
    Corn BW, et al. Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: a multivariate analysis. J Clin Oncol. 1994;12(3):510–5.CrossRefGoogle Scholar
  47. 47.
    Algan O, et al. Improved outcome in patients treated with postoperative radiation therapy for pathologic stage I/II endometrial cancer. Int J Radiat Oncol Biol Phys. 1996;35(5):925–33.CrossRefGoogle Scholar
  48. 48.
    Carey MS, et al. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol. 1995;57(2):138–44.CrossRefGoogle Scholar
  49. 49.
    Small Jr W, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71(2):428–34.CrossRefGoogle Scholar
  50. 50.
    Shih KK, et al. Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer. Gynecol Oncol. 2013;128(3):535–9.CrossRefGoogle Scholar
  51. 51.
    Jhingran A, et al. Vaginal motion and bladder and rectal volumes during pelvic intensity-modulated radiation therapy after hysterectomy. Int J Radiat Oncol Biol Phys. 2012;82(1):256–62.CrossRefGoogle Scholar
  52. 52.
    Heron DE, et al. Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms. Gynecol Oncol. 2003;91(1):39–45.CrossRefGoogle Scholar
  53. 53.
    Roeske JC, et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2000;48(5):1613–21.CrossRefGoogle Scholar
  54. 54.
    Jhingran A, et al. A phase II study of intensity modulated radiation therapy to the pelvis for postoperative patients with endometrial carcinoma: radiation therapy oncology group trial 0418. Int J Radiat Oncol Biol Phys. 2012;84(1):e23–8.CrossRefGoogle Scholar
  55. 55.
    Klopp A, et al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2014;4(3):137–44.CrossRefGoogle Scholar
  56. 56.
    Meyer LA, et al. Postoperative radiation therapy for endometrial cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol. 2015;33(26):2908–13.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Onyinye Balogun
    • 1
  • Stella Lymberis
    • 1
  • Peter B. Schiff
    • 1
    Email author
  1. 1.Department of Radiation Oncology, Laura and Isaac Perlmutter Cancer CenterNYU School of Medicine, NYU Langone Medical CenterNew YorkUSA

Personalised recommendations